ARMPNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Armata Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$3.07−0.30 (-8.90%)
Close on Oct 19, 2026
- Market cap
- $190.47M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -167.9% | -132.6% | 130.4% | |
| Return on assets | -75.9% | -68.3% | -212.8% | |
| Current ratio | 1.78 | 1.62 | 1.19 | |
| Interest coverage | -3896.3× | -34.4× | – | |
| Diluted shares | 0M | 16M | 36M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Armata Pharmaceuticals generated $166.79M from operations and spent $14.08M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$166.79M
Used
$14.08M
Capital expenditure$14.08M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$173.80M
- Cash generatingOperating cash flow above zero-$25.76M
- Return on assets improvedROA up on the prior year-19.2% → -201.1%
- Earnings backed by cashOperating cash flow above net income-$25.76M vs -$173.80M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.23 → 1.19
- No dilutionShare count did not rise59M → 36M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –